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Objectives. To compare the prevalence of diabetic peripheral neuropathy (DPN) and that of cardiac autonomic neuropathy (CAN)
between South Asians and White Caucasians with type 2 diabetes and to explore reasons for observed differences. Methods. A
cross-sectional study of casually selected South Asian and White Caucasian adults attending a hospital-based diabetes clinic in
the UK. DPN and CAN were assessed using the Michigan Neuropathy Screening Instrument (MNSI) and heart rate variability
testing, respectively. Results. Patients (𝑛 = 266) were recruited (47.4% South Asians). DPN was more common inWhite Caucasians
compared to SouthAsians (54.3% versus 38.1%,𝑝 = 0.008). Foot insensitivity as assessed by 10 gmonofilament perceptionwasmore
common in White Caucasians (43.9% versus 23.8%, 𝑝 = 0.001). After adjustment for confounders, White Caucasians remained
twice as likely to haveDPN as SouthAsians, but the impact of ethnicity became nonsignificant after adjusting for adipositymeasures
or height. No difference in prevalence of standardized CAN test abnormalities was detected between ethnicities. Skinmicrovascular
assessment demonstrated that South Asians had reduced heating flux but preserved acetylcholine response. Conclusions. South
Asians with type 2 diabetes have fewer clinical signs of DPN compared to White Caucasians. Differences in adiposity (and its
distribution) and height appear to explain these differences.
1. Introduction
Diabetic neuropathy (DN) is the most common form of
neuropathy in the Western world and one of the most
troublesome complications of diabetes mellitus, resulting in
great morbidity (e.g., it is the leading cause of nontraumatic
lower limb amputation), mortality, and significant economic
burden [1–3]. The reported prevalence of diabetic periph-
eral neuropathy (DPN) and diabetic autonomic neuropathy
(DAN) varies significantly depending on the population
studied and the methods used [2–9]. Many factors have
been implicated in the pathogenesis of DN including non-
metabolic factors such as age and height [3, 6, 10, 11], as well
as metabolic factors such as hyperglycemia, hypertension,
dyslipidemia, waist circumference, and obesity [3, 12–14].
Thesemetabolic factors stimulatemultiple pathways resulting
in direct cellular damage and functional and/or structural
defects involving the extracellularmatrix and/ormicrovascu-
lature [15, 16]. Disease-modifying treatments are still lacking
(with the exception of improved glycaemic control) [12,
15]. Hence, improved understanding of DN pathogenesis is
important in order to identify new treatment targets [15].
South Asians with type 2 diabetes seem to be at lower
risk of developing DPN resulting in a lower incidence of
foot ulcerations and amputations [17–19]. Such a difference
is surprising as diabetes-related complications have predom-
inantly a vascular aetiology, with South Asian patients at
higher risk of cardiovascular disease compared to White
Caucasians with type 2 diabetes [20]. However, the previous
reports that identified this difference either conducted a very
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limited assessment of DPN [17, 20] or utilized a patient
population with a low prevalence of diabetes complications
and could not detect a difference in DPN prevalence using
routine clinical examination techniques [18]. Critically, the
underlying factors that could explain such differences inDPN
prevalence have not been fully explored. One previous report,
based on a primary care population in the UK, suggested that
differences in height and transcutaneous partial pressure of
oxygen (TCpO2) were responsible for the lower prevalence
of DPN in South Asians [18]. This report, however, did not
adjust for a wide range of possible confounders such as
obesity, alcohol intake, and triglycerides (amongst others), all
of which are well established risk factors for neuropathy.
In contrast to DPN, the impact of ethnicity on CAN in
patients with type 2 diabetes has received little attention, with
the exception of a single report that compared the 𝐸/𝐼 ratios
between South Asians and White Caucasians [18]; hence
there is need for further studies utilizing more sensitive and
detailed assessments of CAN.
The primary aim of this study was therefore to explore
the possible metabolic, demographic, and microvascular
differences that might explain the lower prevalence of DPN
in South Asians with type 2 diabetes compared toWhite Cau-
casians. Secondary aims included comparing the prevalence
of clinically detectable DPN and that of cardiac autonomic
neuropathy (CAN) in South Asians and White Caucasians
with type 2 diabetes receiving hospital-based diabetes care.
2. Materials and Methods
This is a secondary analysis of an ongoing project with
the aim of exploring the mechanisms contributing to the
development of microvascular complications in patients with
type 2 diabetes [21–24]. We have conducted a cross-sectional
study of casually selected South Asian or White Caucasian
adults with type 2 diabetes recruited from the clinic of a
hospital-based diabetes centre in the UK. Subjects excluded
were those under the age of 18, not of either South Asian or
White Caucasian ethnicity, or known to have neuropathy for
other reasons apart from diabetes (<1%).
Patients were recruited casually from the outpatient
diabetes departments of twodifferent hospitals in theUK.The
majority of participants (86%) were recruited from the Heart
of England NHS Foundation Trust in Birmingham, UK,
which has a large SouthAsian populationwith type 2 diabetes
(approximately 40% of the total clinic). These factors suggest
that our sample is representative and the two ethnicities are
comparable. Patients who originated from India, Pakistan, Sri
Lanka, or Bangladesh were considered to be of South Asian
origin. Ethnicity was determined using the UK decennial
census by the study participants.The project was approved by
the Warwickshire Research Ethics Committee (REC number
08/H1211/145). Patients were consented prior to participation
in the study.
DPN was assessed using the Michigan Neuropathy
Screening Instrument (MNSI) which is a validated, 2-compo-
nent tool designed to facilitate the early diagnosis of DPN [4,
25–29]. The questionnaire component (MNSIq) comprises
15 questions seeking to characterize sensory disturbance but
also peripheral vascular disease and general asthenia [25].
The examination component (MNSIe) comprises a limited
foot inspection to identify deformity, skin abnormalities, and
ulceration, coupled with an assessment of the vibratory per-
ception and ankle tendon reflexes [25]. For the purpose of
this study, DPN was diagnosed if the MNSIe score was >2
and/or MNSIq was ≥7 [27]. We have also used perception to
a 10 g monofilament (applied to 10 positions, the tip of each
toe, under 3 metatarsal heads, the plantar surface of the foot,
and the dorsal space between the first and second toe) as
a test for foot insensitivity; an abnormal monofilament test
was defined as < 8 correct responses [30]. The relationship of
ethnicity to neuropathic symptoms was also assessed using
the MNSIq.
CAN was assessed using heart rate variability (HRV) and
was analyzed using the continuous wavelet transform meth-
ods to generate numerical and graphical data using the ANX-
3.0 software, ANSAR Inc., Philadelphia, PA.TheR-R intervals
were recorded and the HRV was plotted in the frequency
domain to separate the high-frequency (Rfa, 0.15 to 0.4Hz)
from the low-frequency (Lfa, 0.04 to 0.15Hz) components
by spectral analysis. HRV and BP were recorded with the
patient in sitting position during resting, deep breathing,
Valsalvamaneuver, and standing position [31]. Data recorded
included the𝐸/𝐼 (expiratory/inspiratory) ratio, Valsalva ratio,
30 : 15 ratio, frequency domain analysis with respiratory
adjustment (adjusted low frequency (Lfa), adjusted respir-
atory frequency (Rfa), and Lfa/Rfa), and time domain anal-
ysis including standard deviation of beat-to-beat intervals
(sdNN), root mean square of successive differences (rmsSD),
and the proportion ofNN50 (pNN50). For the purpose of this
study, a diagnosis of CAN was made when 2 or more of the
following tests were abnormal:𝐸/𝐼 ratio, Valsalva ratio, 30 : 15
ratio, and postural drop in BP (drop of 20mmHg in systolic
or 10mmHg in diastolic BP) [2]. Age-related normal values
for 𝐸/𝐼, Valsalva, and 30 : 15 ratios were defined as previously
reported [32].
Microvascular and endothelial assessment were per-
formed on a casually chosen subset of patients (𝑛 = 71)
using Laser speckle contrast imaging (Moor Instruments Ltd.,
Devon, UK) which has been shown to be reproducible [33].
All patients were approached to have the vascular/endothelial
assessment and the test was performed on all those who
agreed.The SouthAsians andWhite Caucasians in this subset
had similar characteristics to those in the total study popu-
lation reported in Table 1. Microvascular blood flow (mea-
sures in arbitrary perfusion units (APU)) was assessed at the
left mid-thigh level. This site was chosen to minimise the
impact of any peripheral vascular disease in the lower limbs.
Measurements were taken with the patient in a semirecum-
bent position in a room temperature of 22-23∘C following 15
minutes of patients acclimatisation [34]. Imaging was per-
formed over 20 minutes, and all measurements were taken
simultaneously. Blood flow was measured at baseline (for 20
minutes) and following maximal dilatation following heating
to 44∘C. Endothelial function was measured following the
iontophoresis of 1% acetylcholine (Ach) and 2% sodium
nitroprusside (SNP) (5 pulses over 5 minutes). Data are pre-
sented as absolute values, conductance (measured as flux
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Table 1: Summary of baseline characteristics in relation to ethnicity. Data are presented as median (IQR) or mean ± 1SD depending on data
distribution. The percentages represent % of participants in the ethnic group. STR: sight threatening retinopathy defined as preproliferative
or proliferative retinopathy or maculopathy or previous laser treatment. TIA: transient ischaemic attack. PVD: peripheral vascular disease.
South Asians
(𝑛 = 126)
White Caucasians
(𝑛 = 140) 𝑝 value
Age (years) 54.9 ± 12.5 59.2 ± 10.8 0.003
Male (%) 60.3 56.4 0.521
Smoking (current or ex-smoker) 30.2 50.7 0.001
Alcohol (%) 2.4 47.9 <0.001
Diabetes duration (years) 11.0 (7.0–18.0) 10.5 (5.0–16.0) 0.153
BMI (kg/m2) 30.1 (26.5–33.6) 35.3 (31.8–41.4) <0.001
Waist circumference (cm) 103.2 (96.9–113.1) 117.2 (109.2–129.4) <0.001
Hip circumference (cm) 102.5 (97–112.25) 120.0 (108.6–131.75) <0.001
Waist/hip ratio 1.00 ± 0.06 0.99 ± 0.11 0.276
Neck circumference (cm) 39.0 (36.9–41.8) 43.0 (39.6–47.0) <0.001
Height (cm) 164.5 ± 8.9 167.1 ± 12.3 0.051
Neck height ratio 0.24 ± 0.02 0.26 ± 0.03 <0.001
Systolic blood pressure (mmHg) 126.0 (115.5–138.5) 130.0 (124.5–140.0) 0.008
Diastolic blood pressure (mmHg) 77.5 (70.0–84.5) 79.0 (73.6–85.9) 0.032
HbA1c (%) 8.0 (7.16–9.20) 8.0 (7.23–9.19) 0.868
Total cholesterol (mmol/L) 3.7 (3.3–4.3) 3.7 (3.3–4.4) 0.637
Triglycerides (mmol/L) 1.8 (1.1–2.4) 1.7 (1.3–2.5) 0.550
HDL (mmol/L) 1.1 (0.9–1.2) 1.1 (0.9–1.3) 0.217
TSH (mU/L) 1.6 (1.0–2.3) 1.9 (1.4–2.3) 0.024
Estimated GFR (mL/min/1.73m2) 90.0 ± 25.5 83.7 ± 27.1 0.053
Oral antidiabetes agent (%) 91.3 92.9 0.632
Sulphonylureas (%) 42.1 30.7 0.054
Insulin (%) 50.0 57.9 0.199
Insulin dose (units) 80.0 (44.0–118) 67.0 (52.0–97.5) 0.649
GLP-1 analogues (%) 4.0 17.1 0.001
Lipid lowering treatment (%) 81 85 0.379
Antihypertensive therapy 74.6 84.3 0.05
Antiplatelet agents (%) 65.6 64.5 0.847
Albuminuria (%) 38.6 34.6 0.536
STR (%) 36.0 36.8 0.908
Ischaemic heart disease (%) 23.0 17.1 0.231
CABG (%) 13.5 10.0 0.375
Stroke/ TIA (%) 9.5 10.7 0.748
PVD (%) 2.4 8.6 0.029
divided by mean arterial pressure in order to account for
differences in BP) and as percentage of maximal dilatation
flow as recommended by previous reports [34]. Heating res-
ponse represented maximum dilatation [34].
Data analysis was performed using SPSS 15.0 software
(SPSS Inc., Chicago, USA). Data are presented as mean ± 1SD
or median (IQR) depending on data distribution. Normality
testing was performed using histograms and the Shapiro-
Wilk test. Independent continuous variables were compared
using the independent 𝑡-test or the Mann–Whitney test. Cat-
egorical variables were compared using the Chi square test.
The Bonferroni correction was applied to define statistical
significance when the components of the MNSIe and MNSIq
were compared between the ethnicities. In order to iden-
tify independent predictors of DPN and CAN (separately),
logistic regression models were applied. Variables included
in logistic regression models were tested for multicollinearity
using the tolerance test and the variance inflation factor; no
evidence of multicollinearity was found in the logistic regres-
sion models used in this paper. Adiposity measures (BMI,
waist, and neck circumferences) were included in the regres-
sion models separately due to the high correlation between
these variables. A 𝑝 value <0.05 was considered significant
throughout the manuscript except when stated otherwise.
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3. Results
Patients (𝑛 = 266) were included in this analysis, 47.4%
of whom were South Asian. South Asians were shorter and
younger but had similar duration of known diabetes. South
Asians also had lower adiposity measurements, BP, TSH
levels, smoking, and alcohol intake (Table 1).The prescription
of antihypertensive and GLP-1 analogue treatment was also
lower in South Asians (Table 1). The prevalence of other
microvascular complications and past medical history of
coronary artery diseasewas similar between ethnicities, while
SouthAsians had lower prevalence of peripheral vascular dis-
ease (PVD) (Table 1) which is consistent with other previous
reports [17].
DPN was more common in White Caucasians compared
to South Asians (54.3% versus 38.1%, 𝑝 = 0.008). Foot insen-
sitivity, as assessed by abnormal monofilament perception,
was also more common in White Caucasians (43.9% versus
23.8%, 𝑝 = 0.001) (Table 2). Analysis of patient symptom
scores demonstrated that symptoms consistent with sensory
deficit were not different between ethnic groups whereas
pain/discomfort symptoms related to were nonsignificantly
more common in South Asians (Table 2). White Caucasian
patients had more abnormalities on all aspects of neuropathy
examination and, consistent with our findings with the mon-
ofilament, reported more open sores on the foot (Table 2).
To determine the potential influence of demographic and
metabolic differences between ethnicities on the prevalence
of DPN, logistic regression models with increasing complex-
ity were used (Table 3).The association between ethnicity and
DPN remained significant, despite adjusting for a wide range
of possible confounders. This association was attenuated by
age and a history of PVD and was abolished after adjusting
for height and adiposity measures (with the exception of
waist/hip ratio) (Table 3), suggesting that ethnic differences in
DPNprevalence can bemainly explained by the differences in
height and adiposity between the ethnic groups. All adiposity
measures were independently associated with DPN despite
adjusting for all possible confounders listed in Table 3 (except
height and BMI which were not used in the same model)
[BMI: odds ratio (OR) 1.076 (95% CI 1.026 to 1.130), 𝑝 =
0.003; waist circumference: OR 1.040 (95% CI 1.016 to 1.064),
𝑝 = 0.001; neck circumference: OR 1.143 (95% CI 1.045 to
1.250), 𝑝 = 0.003]. Other independent associations included
previously reported measures such as age, diabetes duration,
and insulin treatment [13, 14, 35].
Unlike clinically apparent DPN, we found no difference
in prevalence of abnormalities of standardized cardiovascular
autonomic function tests between ethnicities (40.9% versus
40.9%, 𝑝 = 0.995). Frequency and time domain analysis,
however, revealed more extensive deficits in the White
Caucasian compared to the South Asian cohort (Table 4).
However, these differenceswere not significant after adjusting
for possible confounders (such as age). Diabetes duration
[OR 1.084 (95% CI 1.028 to 1.144), 𝑝 = 0.003] and the use of
calcium channel blockers [OR 0.292 (95% CI 0.123 to 0.694),
𝑝 = 0.005] were found to be independently associated with
CAN after adjusting the data, but not ethnicity [OR 1.077
(95% CI 0.473 to 2.452), 𝑝 = 0.860].
Microvascular and endothelial assessment demonstrated
significant differences between the two ethnicities. South
Asians had similar baseline skin flux and conductance and
markedly lower maximal dilatation following heating despite
a similar SNP response but had preserved endothelial-
dependant vasodilatation (Table 5). Indeed, endothelial-
dependent vasodilatation significantly exceeded that mea-
sured in the White Caucasian population when expressed
as the ratio of Ach-induced to heating-induced flux [34]
(Table 5).
4. Discussion
We have compared the prevalence of DPN and that of CAN
between South Asians and White Caucasians with type 2
diabetes from a hospital-based care setting. We then tried to
determine whether specific metabolic and/or demographic
factors could explain observed differences in the prevalence
of clinically detectable DPN and CAN between these groups.
Our study clearly demonstrates that DPN and foot insen-
sitivity are less common in South Asian patients and impli-
cates height and adiposity as potential factors underlying this
difference. Furthermore, we found that total body (BMI),
visceral (waist circumference), and upper body (neck circum-
ference) fat were independently associated with DPN after
adjusting for a range of confounders.
Our diabetes centre serves an area that has a high
proportion of South Asians, although the majority of the
general population are White Caucasians (a reflection of the
much higher prevalence of type 2 diabetes in South Asians
in the UK and elsewhere). Both ethnicities live in the same
geographical area, have similar deprivation scores, and are
referred to our clinic by primary care physicians using the
same referral guidelines which are preagreed with our centre.
Furthermore, there are no differences in clinic attendance
rates between the ethnicities at our centre. Moreover, our
population of South Asians and White Europeans with type
2 diabetes has similar characteristics (such as age, gender,
smoking, alcohol, BMI, and HbA1c) to those described in
previous reports in primary care in other localities in the
UK. As our study population was hospital-based and with
consequently more advanced disease, our findings are not
necessarily generalizable to the general population of patients
with type 2 diabetes (please see below) [18].
Our data demonstrating a lower prevalence of DPN in
South Asian subjects are consistent with other reports [17–
19] but extend these findings by demonstrating significant
differences detectable by routine clinical examination and
the novel finding that obesity (and its distribution) explains,
at least in part, the ethnic differences in DPN prevalence.
In addition, previous study populations exploring the rela-
tionships of DPN and ethnicity were drawn from Primary
Care Practices in the UK which was reflected in the shorter
duration of diabetes, the lower prevalence of microvascular,
andmacrovascular complications and the less frequent use of
insulin and lipid lowering treatments [18, 19], while our study
extends the findings to hospital-based population. Our study
patients were drawn from a population receiving hospital-
based diabetes care and are therefore representative of a more
Journal of Diabetes Research 5
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Table 3: Assessing the impact of possible confounders on the association between ethnicity and DPN (based on MNSI) using logistic
regression models with increasing complexity. The odds ratios reported are the odds for having DPN in White Caucasians to South Asians.
BP: blood pressure; eGFR: estimated glomerular filtration rate; PVD: peripheral vascular disease; BMI: body mass index.
Model Nagelkerke 𝑅2 Odds ratio 95% confidenceinterval 𝑝 value
Unadjusted: ethnicity 0.035 1.930 1.182–3.149 0.009
Model 1: ethnicity + age + gender 0.091 1.684 1.016–2.793 0.043
Model 2: ethnicity + age + gender + alcohol intake
+ smoking + BP + diabetes duration + HbA1c +
lipids∗ + TSH + eGFR + glucose lowering
treatments$ + antihypertensivesm + antiplatelets@
+ lipid lowering therapy∧
0.224 1.987 1.069–3.693 0.030
Model 3: Model 2 + PVD 0.237 1.887 1.008–3.530 0.047
Model 4: Model 3 + height 0.244 1.766 0.932–3.348 0.081
Model 5: Model 3 + BMI 0.279 1.169 0.581–2.352 0.661
Model 6: Model 3 + waist circumference 0.290 1.077 0.532–2.180 0.837
Model 7: Model 3 + neck circumference 0.278 1.087 0.528–2.237 0.822
∗Adjustment for lipids included adjustment for total cholesterol, triglycerides, and HDL individually.
$Adjustment for glucose lowering treatments included adjustment for metformin, sulphonylurea, glitazones, DPP-4 inhibitors, insulin, and GLP-1 analogues
individually. No other glucose lowering treatment was used in our study population.
mAdjustment for antihypertensives included adjustment for ACE inhibitors, angiotensin 2 blockers, beta blockers, alpha blockers, calcium antagonists, and
diuretics individually.
@Antiplatelets included aspirin and clopidogrel.
∧Adjustment for lipid lowering therapy included adjustment for statins, ezetimibe, and fibrates individually.
Table 4: Differences in heart rate variability, spectral analysis, and
time-domain and frequency-domain parameters between South
Asians andWhite Caucasianswith diabetes. Nonsignificant compar-
isons from the HRV and frequency and time domain analysis have
not been included. Data are presented as median (IQR).
South Asians
(𝑛 = 115)
White
Caucasians
(𝑛 = 110)
𝑝 value
30 : 15 ratio 1.26 (1.11–1.60) 1.19 (1.08–1.37) 0.027
Baseline Lfa 0.95 (0.42–2.14) 0.60 (0.27–1.38) 0.041
Baseline Rfa 0.54 (0.21–1.19) 0.35 (0.15–0.80) 0.032
Deep breathing Lfa 0.70 (0.29–1.84) 0.44 (0.16–1.35) 0.035
Standing Lfa 1.13 (0.41–2.73) 0.69 (0.23–1.43) 0.018
advanced, complicated disease, which has not previously
been assessed. This difference in population characteristics
may underlie the previously reported inability to detect sig-
nificant differences in DPN prevalence using the Neuropathy
Disability Score (NDS), instead relying upon findings from
nerve electrophysiology [18]. Moreover, although not directly
assessed, preservation of themicrocirculation was implicated
as a potential contributor to the lower risk of DPN and foot
ulceration observed in South Asian patients [18]. There was,
however, no adjustment performed for adiposity.
Our study confirms previous reports that foot ulceration
is lower in South Asian compared to White Caucasian
patients with type 2 diabetes [17]. This finding is consistent
with our observation of relative preservation of 10 g monofil-
ament perception in South Asian patients. Interestingly, the
overall prevalence of neuropathic symptoms ascribable to
Table 5: Assessment of microvascular blood flow and endothelial
function in SouthAsians andWhite Caucasianswith type 2 diabetes.
Data presented as median (IQR) or ratios. Blood flux was measured
in arbitrary perfusion units (APU). Conductance is the measure of
dividing flux by the mean arterial pressure.
South Asians
(𝑛 = 33)
White Caucasians
(𝑛 = 38)
𝑝 value,
unadjusted
Flux
Baseline 23.10 (17.30–35.15) 24.20 (15.70–35.22) 0.986
Heating 140.10(107.30–169.05)
174.00
(143.12–207.62) 0.006
Ach 112.00(84.80–135.50) 107.40 (73.62–142.77) 0.991
SNP 102.80 (66.70–141.10) 127.30 (81.60–172.60) 0.170
Conductance
Baseline 0.27 (0.18–0.40) 0.27 (0.17–0.37) 0.653
Heating 1.58 (1.22–1.90) 1.77 (1.50–2.19) 0.029
Ach 1.26 (0.88–1.38) 1.07 (0.77–1.53) 0.612
SNP 1.12 (0.75–1.51) 1.30 (0.88–1.84) 0.273
Flux in relation to maximum vasodilatation
Baseline 0.17 (0.12–0.24) 0.15 (0.10–0.21) 0.074
Ach 0.78 (0.62–0.91) 0.63 (0.43–0.76) 0.01
SNP 0.78 (0.46–1.01) 0.75 (0.51–0.94) 0.596
DPN, however, was comparable across ethnicities with simi-
lar percentages reporting symptoms consistent with sensory
loss but (nonsignificantly) more South Asian patients report-
ing neuropathic pain. It is known that South Asians have a
higher prevalence of vitamin D deficiency [36], which might
Journal of Diabetes Research 7
contribute to differences in some symptoms, particularly
generalized weakness.
Our results showed that age, diabetes duration, and
insulin treatment were independently associated with DPN,
as has been previously reported [13, 14, 35]. The relationship
between DPN and insulin is interesting, but due to the cross-
sectional nature of this study, causation cannot be proven.
Intensive insulin treatment by improving metabolic control
has been shown to have beneficial effects on DPN [12].
Patients might have been started on insulin because of the
presence of DPN and other microvascular complications in
order to slow progression. On the other hand, our data do
not show a relationship between DPN and other risk factors
such as triglycerides [37]; this could be related to our sample
size, the different characteristics of our study population, or
the high proportion of patients that were on lipid lowering
therapy.
SouthAsians have different body fat distribution toWhite
Europeans and tend to have greater fat mass than White
Europeans for the sameBMI level [38–40]. In order to address
this issue, we used different measures of adiposity including
BMI, waist circumference, and neck circumference, all of
which were greater in White Europeans compared to South
Asians in our study. All of these adiposity measures removed
the impact of ethnicity on DPNwhen added to the regression
model.
Our data, demonstrating BMI, waist circumference, and
neck circumference as independent predictors of DPN, is
potentially of mechanistic importance. Neck circumference
is associated with cardiometabolic risk factors [41] and with
obstructive sleep apnoea (OSA) [42], a disease that is very
common in type 2 diabetes (up to 86% prevalence) [43]
and is known to be associated with endothelial dysfunction
and abnormal blood flow regulation [44]. Interestingly, neck
circumference has recently been identified as an independent
predictor of diabetic retinopathy [45].
Maximal skin blood flow of the lower limb on heating
was reduced but endothelial function preserved in South
Asian compared toWhite Caucasians with type 2 diabetes. In
contrast, there were no significant differences in the response
to SNP. To our knowledge, this is the first evaluation of skin
microvascular flow regulation in South Asian patients with
diabetes. Heating to 44∘C leads to maximal vasodilatation
which corresponds to the maximal vasodilatory capacity
[34]. Deficits in heating responses have been associated with
increased prevalence of cardiovascular disease [46, 47] and so
our findings might have relevance for the higher cardiovas-
cular disease risk observed in South Asians with type 2
diabetes [20].
In contrast to the heating response, the response to Ach
(when measured as a ratio of maximal vasodilatation) was
greater in South Asians, suggesting relative preservation of
endothelial-dependent vasodilatation. The response to Ach
is thought to reflect both an axon reflex and prostaglandin-
mediated component [34] which might, therefore, be of rele-
vance to the lower prevalence of DPN and foot complications
in these subjects. In patients without diabetes, heating res-
ponse was not different [47] while SNP was lower [48] in
South Asians compared toWhite Caucasians whenmeasured
in the forearm.Our data are also consistentwith the finding of
relative preservation of TCpO2 in South Asian subjects with
diabetes [18].
Unlike DPN, there was no difference in the prevalence
of abnormalities of standardized CAN tests between South
Asian and White Caucasian patients, although differences
in spectral analysis suggested more preserved autonomic
function in South Asians. This highlights the fact that the
pathogenesis of DPN and CAN may not be the same and
understanding such differences will be important to develop
targeted treatments. Differences in CAN prevalence between
South Asian and White Caucasian patients with type 2
diabetes have been previously assessed using the 𝐸/𝐼 ratio
and the postural drop in BP as markers of CAN [18]. In this
previous report, there was no difference in the postural drop
between ethnicities (consistent with our findings), but there
was a significant difference in the change in heart rate asso-
ciatedwith deep breathing between ethnicities. It is difficult to
directly compare our results with the results from this report,
as we performed a more extensive assessment of CAN and
we have presented our 𝐸/𝐼 ratio data as categorical variable
rather than an absolute change in heart rate.
There are some limitations of our study, particularly
the differences in baseline parameters such as age, height,
BP, smoking, and alcohol consumption between the ethnic
groups which might have affected the associations observed
in our study. However, the principal findings of our study
remained significant after adjusting for a wide range of
possible confounders. Matching ethnicities for some of the
baseline parameters might have been preferred, but such
precise matching is difficult (particularly regarding age and
adiposity measures) due to the significant demographic dif-
ferences that exist between our local South Asian and White
Caucasian population with type 2 diabetes. The relatively
small size of our samplemight have obscured the relationship
between CAN and ethnicity. Nonetheless, this sample size
was adequate to detect a difference in the prevalence of DPN
consistent with the construct that differences in the patho-
genesis of peripheral and autonomic neuropathymay exist. In
addition, this is a cross-sectional study and hence causation
cannot be proven. Additionally, there is the possibility of
self-selection bias (i.e., patients withmicrovascular complica-
tions preferentially agreeing to participate), which cannot be
entirely excluded. However, all patients attending a general
diabetes clinic were approached about willingness to enrol
in the study and we are unaware of an ethnicity-mediated
self-selection bias which would affect our conclusions. This
is further supported by the similar prevalence of diabetic
retinopathy between the two ethnicities. Finally, the MNSI is
not the “gold standard” for diagnosing DPN but it has been
validated against nerve conduction studies [25, 29] and has
been usedwidely in landmark studies [4, 26, 27, 30].We chose
to use the MNSI (in concert with the 10 g monofilament)
since it offers the advantage of providing robust, meaningful,
clinically detectable end-points.
In summary, clinical signs consistent with DPN are
reduced in South Asian compared to White Caucasian
patients with type 2 diabetes receiving hospital-based dia-
betes care. In contrast, the overall prevalence of neuropathic
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symptoms ascribable to DPN was similar in these ethnic
groups. Differences in height and adiposity appear to explain
the ethnic differences in DPN prevalence; and obesity was
an independent determent of DPN in these populations. We
have also identified a novel association between neck circum-
ference and DPN which might be of pathogenic importance
as neck circumference is associated with cardiometabolic
risk factors and OSA. Endothelial-dependent microvascular
function, but not the response to heating, was also relatively
preserved in South Asian subjects. Future studies are war-
ranted to characterize small nerve fibre loss and dysfunction
in different populations, address the possible role of OSA
in the pathogenesis of DPN, and further explore differences
in microvascular blood flow regulation between different
ethnicities.
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